Drug Type Bispecific antibody |
Synonyms |
Target |
Mechanism CDH17 antagonists(Cadherin-17 antagonists), PD-1 inhibitors(Programmed cell death protein 1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Gastrointestinal Neoplasms | Preclinical | HK | 22 Mar 2024 |